Stockscreener 앱 받기
1.93
0.52%
0.01
시간 외 거래:
1.92
-0.01
-0.52%
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN
Neumora shares slump after depression drug fails in key trial - MSN
William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
William Blair Reiterates "Outperform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MSN
Neumora Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Bank of America Issues Pessimistic Forecast for Neumora Therapeutics (NASDAQ:NMRA) Stock Price - Defense World
Traders Purchase High Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics's SWOT analysis: navacaprant setback tests resilience of CNS-focused biotech stock - Investing.com
Neumora’s Major Setback with Navacaprant Program: Industry Reacts - Zenopa
Stock Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora stock faces skepticism after failed trial, but BofA remains optimistic - Investing.com Canada
Bank of America Cuts Neumora Therapeutics (NASDAQ:NMRA) Price Target to $7.00 - MarketBeat
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
What is William Blair's Estimate for NMRA FY2029 Earnings? - MarketBeat
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - MSN
Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $23.40 - Defense World
Neumora shares look oversold after 80% drop, says Mizuho - Yahoo Finance
Neumora Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Neumora Therapeutics stock reiterated at Buy by analyst following KOASTAL-1 result - Investing.com Canada
Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops - MSN
Mizuho reiterates Outperform on Neumora Therapeutics stock post navacaprant data - Investing.com Canada
Neumora’s KOSTAL-1 Study of Navacaprant Yields Disappointing Results - Contract Pharma
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression - Yahoo Finance
Neumora fails in late-stage trial for depression therapy - MSN
Neumora shares sink following Phase III flop in MDD - MSN
Neumora tanks as KOASTAL-1 study of navacaprant misses - The Pharma Letter
3.95%
2.39%
자본화:
|
볼륨(24시간):